Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

AIMS: We investigated whether the insertion/deletion (I/D) polymorphism of the ACE gene modified the adherence to ACE inhibitors as measured by the discontinuation of an ACE inhibitor, or addition of another antihypertensive drug. METHODS: This was a cohort study among 239 subjects who started ACE inhibitor therapy. A Cox proportional hazard model was used to calculate relative risk (RR). RESULTS: During follow-up there was no significant difference between subjects with the DD, ID or II genotype (DD vs II; RR = 1.17, 95%CI: 0.78, 1.77 and ID vs II; RR = 1.06, 95%CI: 0.73, 1.55) in adherence. CONCLUSIONS: The I/D polymorphism of the ACE gene does not influence the adherence to ACE inhibitors.

Original publication

DOI

10.1111/j.1365-2125.2004.02332.x

Type

Journal article

Journal

British journal of clinical pharmacology

Publication Date

04/2005

Volume

59

Pages

483 - 485

Addresses

Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, The Netherlands.

Keywords

Humans, Hypertension, DNA Transposable Elements, Antihypertensive Agents, Angiotensin-Converting Enzyme Inhibitors, Analysis of Variance, Risk Assessment, Cohort Studies, Prospective Studies, Polymerase Chain Reaction, Patient Compliance, Gene Deletion, Genotype, Polymorphism, Genetic, Aged, Middle Aged